Elsevier, Amsterdam, pp 367378 Hickie I (1999) Nefazodone for patients with chronic fatigue syndrome
1996 Feb;148(2):197-205
discuss with doctor if severe Week 1316: Maintenance Dose (9mg or continuing to 12mg) For 9mg group (maintenance): Side effects stabilize Nausea decreases (2025% still experiencing) Dysesthesia: 8.8% incidence (mild) Body adapting well For 12mg group (final increase): GI effects may temporarily worsen (4045% nausea) Dysesthesia peaks (20.9% incidence) This is the "make or break" dose highest efficacy, highest side effects Duration: 12 weeks adjustment period Week 17+: Long-Term Maintenance Side effects: Nausea: Decreases to 1525% (down from 4045%) Diarrhea: Improves to 1020% Dysesthesia: Stable at 8.820.9% (doesn't worsen) Most people feel "normal" except for reduced appetite Key point: Side effects are WORST during dose escalation (weeks 116)
Mechano growth factor (MGF) is a unique, spliced variant of insulin-like growth factor 1 (IGF-1)
Working With Healthcare Providers For Canadian patients pursuing FDA-approved medications once Retatrutide receives approval, the process typically involves initial consultation to establish obesity diagnosis and discuss treatment options, baseline laboratory work including metabolic panel, lipid profile, and A1C if diabetic, discussion of contraindications and potential drug interactions, prescription and prior authorization if required by insurance, and scheduled follow-up appointments for monitoring
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
